Multimodal Model Predicts Recurrence
FUTURE12
Multimodal Clinical-imaging-pathology-driven Artificial Intelligence Model for Predicting Postoperative Recurrence of Locally Advanced Gastric Cancer
1 other identifier
observational
93
1 country
1
Brief Summary
This study focuses on developing an advanced model that combines clinical information, imaging, and pathology data to predict the likelihood of cancer returning after surgery in patients with locally advanced gastric cancer. By using artificial intelligence (AI), this model analyzes various data sources to create a more accurate prediction of recurrence risk, which can help doctors, patients, and families better understand the chances of recurrence. This AI-driven approach allows healthcare providers to make more informed decisions about personalized follow-up care and potential additional treatments to improve patient outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2024
CompletedFirst Submitted
Initial submission to the registry
November 13, 2024
CompletedFirst Posted
Study publicly available on registry
November 15, 2024
CompletedNovember 15, 2024
November 1, 2024
2.8 years
November 13, 2024
November 13, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Prediction accuracy of postoperative recurrence in locally advanced gastric cancer
The primary outcome measure is the accuracy of the multimodal AI model in predicting the risk of postoperative recurrence in patients with locally advanced gastric cancer. This is assessed by comparing the model's predictions with actual recurrence events over a specified follow-up period, allowing evaluation of its effectiveness in identifying high-risk patients and guiding clinical decisions.
24 months postoperative follow-up
Interventions
This intervention involves a multimodal artificial intelligence (AI) model that integrates clinical data, imaging results, and pathology findings to predict the risk of postoperative recurrence in patients with locally advanced gastric cancer. Unlike traditional methods that may rely on single data sources, this AI-driven model synthesizes multiple types of patient information, offering a comprehensive and personalized prediction of recurrence risk. This approach aims to improve accuracy in identifying high-risk patients, allowing for more tailored follow-up and treatment planning to enhance patient outcomes.
Eligibility Criteria
The study population includes adult patients (aged 18 and older) diagnosed with locally advanced gastric cancer (Stage II or III) who have undergone surgical resection. This population is selected based on the availability of complete clinical, imaging, and pathology data necessary for analysis by the multimodal AI-driven predictive model. The study focuses on assessing the postoperative recurrence risk in this specific group to improve personalized follow-up and treatment planning.
You may qualify if:
- Patients diagnosed with locally advanced gastric cancer (Stage II or III).
- Patients who have undergone surgical resection for gastric cancer.
- Patients with complete clinical, imaging, and pathology data available for analysis.
- Age 18 years or older.
- Patients who provide informed consent to participate in the study.
You may not qualify if:
- Patients with distant metastasis (Stage IV) at the time of diagnosis.
- Patients with incomplete or missing clinical, imaging, or pathology data.
- Patients who have received prior treatment for gastric cancer other than surgical resection.
- Patients with other concurrent malignancies.
- Patients who are unable or unwilling to comply with the study follow-up requirements.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Qun Zhaolead
Study Sites (1)
the Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050011, China
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 24 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
November 13, 2024
First Posted
November 15, 2024
Study Start
January 1, 2022
Primary Completion
October 31, 2024
Study Completion
October 31, 2024
Last Updated
November 15, 2024
Record last verified: 2024-11